Technical Analysis for INFI - Infinity Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 1.28 -3.76% -0.05
INFI closed down 3.76 percent on Thursday, January 17, 2019, on 17 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical INFI trend table...

Date Alert Name Type % Chg
Jan 17 Stochastic Sell Signal Bearish 0.00%
Jan 17 180 Bearish Setup Bearish Swing Setup 0.00%
Jan 17 Wide Bands Range Expansion 0.00%
Jan 17 Overbought Stochastic Strength 0.00%
Jan 16 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -3.76%
Jan 16 Narrow Range Bar Range Contraction -3.76%
Jan 16 Weak + Overbought Other -3.76%
Jan 16 Wide Bands Range Expansion -3.76%
Jan 16 Overbought Stochastic Strength -3.76%
Jan 15 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -3.03%

Older signals for INFI ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Infinity Pharmaceuticals, Inc., a drug discovery and development company, focuses on discovering, developing, and delivering medicines to patients for diseases with significant unmet need. Its lead product candidates include IPI-145 and IPI-443, inhibitors of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K); Retaspimycin HCl, a heat shock protein 90 inhibitor; and IPI-940, an inhibitor of fatty acid amide hydrolase. The company is pursuing a dual development path for IPI-145 in both hematologic malignancies and inflammation. IPI-145 is in an ongoing Phase I dose-escalation trial in patients with advanced hematologic malignancies and in a Phase IIa study in patients with mild, allergic asthma. In addition, the company plans to initiate a Phase II signal-finding study in patients with rheumatoid arthritis. IPI-443 is undergoing preclinical studies to enable Phase I development. Retaspimycin HCl is in a Phase II trial in combination with docetaxel to treat patients with non-small cell lung cancer (NSCLC) and in an exploratory Phase Ib/II trial in combination with everolimus in NSCLC patients with a KRAS mutation. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
Is INFI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 2.92
52 Week Low 1.0
Average Volume 569,437
200-Day Moving Average 1.922
50-Day Moving Average 1.3806
20-Day Moving Average 1.2085
10-Day Moving Average 1.298
Average True Range 0.0945
ADX 18.51
+DI 17.8458
-DI 17.2714
Chandelier Exit (Long, 3 ATRs ) 1.0965
Chandelier Exit (Short, 3 ATRs ) 1.2835
Upper Bollinger Band 1.4225
Lower Bollinger Band 0.9945
Percent B (%b) 0.67
BandWidth 35.415805
MACD Line -0.0106
MACD Signal Line -0.0392
MACD Histogram 0.0286
Fundamentals Value
Market Cap 64.88 Million
Num Shares 50.7 Million
EPS -1.39
Price-to-Earnings (P/E) Ratio -0.92
Price-to-Sales 0.00
Price-to-Book 1.82
PEG Ratio -0.03
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.36
Resistance 3 (R3) 1.37 1.35 1.35
Resistance 2 (R2) 1.35 1.33 1.34 1.34
Resistance 1 (R1) 1.31 1.31 1.30 1.31 1.34
Pivot Point 1.29 1.29 1.29 1.29 1.29
Support 1 (S1) 1.26 1.27 1.25 1.25 1.22
Support 2 (S2) 1.24 1.26 1.23 1.22
Support 3 (S3) 1.20 1.24 1.21
Support 4 (S4) 1.20